ESR1 and breast carcinoma: Several peptide antagonists of LEPR (allo-aca, PEG-LPrA2 and LDFI) have been shown independently to be effective against both estrogen receptor positive (MCF7) or negative (MDA-MB-231) breast cancer xenograft models [54–56].